bioAffinity Technologies (BIAF) Equity Average (2021 - 2026)

bioAffinity Technologies has disclosed Equity Average across 6 years of filings, most recently posting $5.5 million for Q1 2026.

• In Q1 2026, Equity Average rose 170.67% year-over-year to $5.5 million; the TTM figure through Mar 2026 stood at $5.5 million (up 170.67% YoY), while the FY2025 annual figure was $4.9 million, up 32.48% from the prior year.
• Equity Average declined to $5.5 million in Q1 2026, from $8.1 million in the prior quarter.
• Over the last five years, Equity Average for BIAF reached as high as $11.8 million in Q4 2022 and fell as low as -$16.8 million in Q2 2022.
• The 5-year median for Equity Average is $4.3 million (2024), against an average of $2.6 million.
• Annual changes were most pronounced in 2023 — Equity Average soared 460.38% — and 2025, when it tumbled 108.02%.
• A 5-year view of Equity Average shows it stood at $11.8 million in 2022, then sank by 49.88% to $5.9 million in 2023, then tumbled by 51.7% to $2.9 million in 2024, then surged by 182.71% to $8.1 million in 2025, then plunged by 32.39% to $5.5 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $5.5 million, $8.1 million, and $3.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.